Clinical trial · Interventional
Dose Escalation of IPI-493 in Hematologic Malignancies
A Phase 1 Open-Label, Dose Escalation Study Evaluating the Safety and Tolerability of IPI-493 in Patients Experiencing Advanced Hematologic Malignancies With Client Proteins of Hsp90
NCT01193491CI-TRIAL-00017526terminatedPhase 1ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): Drug exposure of retaspimycin HCl was superior to IPI-493, Infinity will focus on Retaspimycin HCL
Summary
Brief summary (as posted)
The purpose of this study is to evaluate the safety, determine the maximum tolerated dose (MTD) and schedule of IPI-493 in patients with hematologic malignancies.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Hematologic Malignancies | Hematopoietic and Lymphoid Cell Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| IPI-493 | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- IPI-493
- interventionNames
- Drug: IPI-493
Primary outcomes (1)
- measure
- Evaluation of Safety Endpoints
- timeFrame
- 1 year
- description
- Safety Endpoints * The incidence of reported adverse events (AEs), serious adverse events (SAEs), concomitant medication use, laboratory test results, electrocardiogram (ECG) results, Eastern Cooperative Oncology Group (ECOG) performance status results, and vital sign results * Maximum tolerated dose, defined as the dose level below the dose at which ≥33% of patients experience a dose limiting toxicity (DLT) Pharmacodynamic Endpoints
Secondary outcomes (2)
- measure
- Evaluation of Efficacy Endpoints
- timeFrame
- 1 year
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * \>/=18 years old * ECOG 0-1 * confirmed hematological malignancy * refractory to available therapy or for which no therapy is available * adequate hepatic, renal function Exclusion Criteria: * active CNS malignancy * prolonged QT interval * significant GI/liver disease * other serious concurrent illness or medical condition
References
Publications (0)
Data not yet available
No reference posted for this study.